From the Guidelines
Istradefylline is not mentioned in the provided evidence, and therefore, its use cannot be recommended based on the given guidelines. However, adenosine, which is related to istradefylline in terms of its mechanism of action as an adenosine receptor antagonist, is discussed in several studies 1. The provided evidence focuses on various medical conditions, including atopic dermatitis, asthma, obesity, coronary artery disease, and supraventricular tachycardia, but does not provide information on istradefylline. Some key points from the evidence include:
- The use of adenosine as a vasodilator in the assessment of coronary artery disease 1
- The role of adenosine in the management of supraventricular tachycardia 1
- The use of ivabradine, a medication that affects the heart rate, in the management of inappropriate sinus tachycardia 1 It's essential to consult the most recent and relevant guidelines for the use of istradefylline in clinical practice.
From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
Istradyfylline Overview
- Istradefylline is an adenosine A2A receptor antagonist used in the treatment of Parkinson's disease (PD) 2, 3, 4, 5, 6.
- It is indicated as an adjunctive treatment to levodopa/carbidopa in patients experiencing "off episodes" 5.
Efficacy and Safety
- Istradefylline has been shown to decrease "off" time in patients with PD receiving optimal dopaminergic therapy 2, 3, 4, 5, 6.
- It has also been demonstrated to improve motor function without worsening dyskinesia 2, 3.
- The results of a systematic review and meta-analysis suggest that istradefylline exhibits an efficient and well-tolerated role in treating PD patients, with a significant difference in efficacy and decreasing OFF time compared to placebo 6.
Potential Benefits
- Istradefylline may also have a role in treating non-motor symptoms (NMS) and cognitive decline in PD patients 4.
- It has been suggested that istradefylline may have neuroprotective effects, although further studies are needed to investigate this potential benefit 3, 4.